Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Aristotle Capital Management LLC

Aristotle Capital Management LLC decreased its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 17.8% during the 1st quarter, Holdings Channel.com reports. The firm owned 130,545 shares of the specialty pharmaceutical company’s stock after selling 28,292 shares during the period. Aristotle Capital Management LLC’s holdings in Jazz Pharmaceuticals were worth $24,680,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of JAZZ. Ruffer LLP purchased a new position in Jazz Pharmaceuticals in the fourth quarter worth approximately $2,425,000. Allianz Asset Management GmbH increased its position in shares of Jazz Pharmaceuticals by 68.2% in the 4th quarter. Allianz Asset Management GmbH now owns 598,832 shares of the specialty pharmaceutical company’s stock valued at $101,801,000 after purchasing an additional 242,892 shares during the last quarter. Capricorn Fund Managers Ltd acquired a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at $1,700,000. Swedbank AB raised its holdings in shares of Jazz Pharmaceuticals by 2.7% in the 4th quarter. Swedbank AB now owns 1,102,974 shares of the specialty pharmaceutical company’s stock valued at $187,506,000 after purchasing an additional 28,882 shares in the last quarter. Finally, Daiwa Securities Group Inc. lifted its position in shares of Jazz Pharmaceuticals by 274.6% during the 4th quarter. Daiwa Securities Group Inc. now owns 8,583 shares of the specialty pharmaceutical company’s stock worth $1,459,000 after purchasing an additional 6,292 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on JAZZ shares. UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their target price for the company from $188.00 to $307.00 in a report on Tuesday, May 19th. Deutsche Bank Aktiengesellschaft lifted their price target on Jazz Pharmaceuticals from $250.00 to $270.00 and gave the stock a “buy” rating in a report on Thursday, July 9th. Canaccord Genuity Group assumed coverage on Jazz Pharmaceuticals in a research report on Thursday, July 16th. They set a “buy” rating and a $290.00 price objective for the company. Robert W. Baird set a $252.00 price objective on Jazz Pharmaceuticals in a report on Wednesday, May 6th. Finally, Royal Bank Of Canada raised their target price on Jazz Pharmaceuticals from $195.00 to $258.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $259.06.

Insider Activity

In related news, Director Mark Douglas Smith sold 1,157 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $230.55, for a total transaction of $266,746.35. Following the completion of the transaction, the director directly owned 9,680 shares of the company’s stock, valued at $2,231,724. This represents a 10.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bruce C. Cozadd sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $240.47, for a total transaction of $1,442,820.00. Following the completion of the sale, the director owned 366,682 shares of the company’s stock, valued at approximately $88,176,020.54. The trade was a 1.61% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,098 shares of company stock valued at $3,131,906 over the last ninety days. 4.10% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ opened at $253.87 on Friday. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.04 and a quick ratio of 1.85. The firm has a market cap of $15.95 billion, a price-to-earnings ratio of -12,687.16, a price-to-earnings-growth ratio of 0.22 and a beta of 0.32. The firm’s fifty day moving average price is $237.37 and its 200 day moving average price is $203.24. Jazz Pharmaceuticals PLC has a 1-year low of $105.00 and a 1-year high of $256.75.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. The company had revenue of $1.07 billion during the quarter. On average, sell-side analysts expect that Jazz Pharmaceuticals PLC will post 21.9 EPS for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.